IKT - NASDAQ
Inhibikase Therapeutics, Inc.
$1.70
-0.88%Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
At a Glance
Live SnapshotInhibikase Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Inhibikase Therapeutics, Inc. Cash Flow Statement
IKT • NASDAQ
| Inhibikase Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||
-48.3M | -27.5M | -19M | -18.1M | -14.8M | -2.8M | -5.7M | -2.2M | -436.1K | -628.7K | |
60.5K | 26.3K | 177.4K | 6.7K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
15.3M | 8.1M | 500.1K | 458.1K | 1.5M | 573.7K | 1.4M | 642.2K | 300.7K | 310.1K | |
5M | 0.0 | 31.5K | 67K | 721.6K | 1.6M | 2.3M | 709.3K | 534.6K | 95.7K | |
55.9K | 204.9K | 234.8K | 171.2K | -1.8M | -464.6K | 1.6M | 1.5M | -32.8K | 193.4K | |
-27.8M | -19.1M | -18.1M | -17.4M | -14.3M | -1.1M | -338.3K | 715K | -126.4K | -29.6K | |
INVESTING ACTIVITIES | ||||||||||
-452K | (0.0) | -14.2K | -243.3K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (243.3K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-39.1M | -60.5M | -29.4M | -20.7M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
41.6M | 23.5M | 41.1M | 5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -243.3K | 0.0 | 0.0 | 0.0 | 87.1K | 0.0 | 0.0 | |
(2.1M) | -37M | (11.7M) | -16M | (0.0) | (0.0) | (0.0) | (87.1K) | (0.0) | (0.0) | |
FINANCING ACTIVITIES | ||||||||||
108.5M | 103.5M | 8.5M | 44.1K | 41.1M | 14.8M | 0.0 | 1.2M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -248.9K | -42.5K | 272.8K | -22.8K | -26.3K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 848.0 | 0.0 | 0.0 | -1.6M | 131K | -23.8K | |
108.5M | 103.5M | 8.4M | -204.8K | 41.1M | 15.1M | -22.8K | -439.2K | 131K | -23.8K | |
CASH FLOW SUMMARY | ||||||||||
82.7M | 47.3M | 2M | -33.6M | 26.8M | 13.9M | -361.1K | 362.9K | 4.6K | -53.3K | |
56.5M | 9.2M | 7.2M | 40.8M | 14M | 18.5K | 379.6K | 16.7K | 12K | 65.4K | |
139.2M | 56.5M | 9.2M | 7.2M | 40.8M | 14M | 18.5K | 379.6K | 16.7K | 12K | |
-27.8M | -19.1M | -18.1M | -17.6M | -14.3M | -1.1M | -338.3K | 715K | -126.4K | -29.6K |
SEC Filings
IKT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 07, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 19, 2025 | December 19, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 21, 2025 | November 20, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 20, 2025 | November 20, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 14, 2025 | November 14, 2025 | 2025 |
Related Guides
Continue your IKT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.